SEC31B

Across TCGA pan-cancer cohorts, SEC31B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SEC31B data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SEC31B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEC31B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and SCLC are the cancer types where SEC31B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.182	0.551	<.001	44	view →
UCEC	DFS	Median	All	0.977	0.826	.010	16	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	15	view →
LIHC	OS	Median	All	0.119	0.704	.007	15	view →
PAAD	OS	Median	All	0.110	0.640	<.001	12	view →
SKCM	OS	Median	III,IV	1.000	0.685	.017	9	view →
STAD	OS	Median	II,III,IV	0.909	0.403	.039	6	view →
PRAD	DFS	Median	All	0.619	0.886	.044	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SEC31B–BLCA (OS)

Open the BLCA breakdown →